目的：探讨CT灌注成像对宫颈鳞癌新辅助化疗后预后高危因素的预测价值。方法：选取2011年5月—2015年8月在兰州大学第一医院接受新辅助化疗并手术的51例宫颈鳞癌患者，根据术后病理是否存在预后高危因素及短期预后将其分为无高危因素组（n=36，70.59%）和高危因素组（n=15，29.41%），对两组的CT灌注参数及临床资料作回顾性分析，探讨其对宫颈鳞癌新辅助化疗后预后高危因素的影响。结果：高危因素组中BF、化疗后肿瘤最大直径大于无高危因素组，差异有统计学意义（P<0.05），且与预后高危因素呈正相关（r=0.420，P=0.002；r=0.296，P=0.035）。FIGO分期、病理分级和化疗前肿瘤最大直径、BV、permeability、TTP与宫颈鳞癌新辅助化疗预后高危因素无相关性（P>0.05）。多因素Logistic回归分析及ROC显示BF为宫颈鳞癌新辅助化疗预后高危因素的独立影响因素并能够对其做出较为准确的预测AUC=0.810，P=0.001，95%CI（0.682~0.918）。结论：BF对宫颈鳞癌新辅助化疗后是否存在预后高危因素具有较高的预测价值。当BF≥46.64 mL/（100 mL·min）时，预测预后高危因素的敏感度、特异度和准确度分别为86.67%（13/15）、94.44%（34/36）和92.16%（47/51）。
Abstract
Objective: To explore the predictive value of CT perfusion imaging for predicting the prognostic high-risk factors of cervical squamous carcinoma after neoadjuvant chemotherapy. Methods: The 51 patients who had cervical squamous carcinoma and underwent neoadjuvant chemotherapy before surgery between 2011 May and 2015 August in the First Hospital of Lanzhou University were selected. Based on the prognostic high-risk factors of pathology test and short-term prognosis, the cases were divided into two groups: non-high-risk factors(n=36, 70.59%) and high-risk group(n=15, 29.41%). CT perfusion parameters and clinical data were retrospectively analyzed to investigate the high-risk prognostic factors. Results: Two indexes of the high-risk group cases, the BF(blood flow) and the maximum diameter of the tumor post chemotherapy, were statistically significant higher than another group(P<0.05). The high-risk prognostic factors were positively correlated with BF and the maximum diameter of tumor after neoadjuvant chemotherapy(r=0.420, P=0.002; r=0.296, P=0.035). FIGO staging, pathological grade, the initial diameter of the tumor, BV, permeability and TTP were not correlated with the high-risk prognostic factors(P>0.05). Multivariate logistic regressionn analysis showed BF was an independent predictor to predict the existence of high-risk prognostic factors in cervical squamous carcinoma after neoadjuvant chemotherapy. BF can predict the?prognostic results accurately AUC=0.810, P=0.001, 95%CI(0.682~0.918). Conclusion: BF had significant predictive value as a prognostic high-risk factor of cervical squamous carcinoma after neoadjuvant chemotherapy. Using BF equal to or greater than 46.64 mL/(100mL·min) to predict the existence of high-risk prognostic factors got 86.67%(13/15), 94.44%(34/36) and 92.16%(47/51) in sensitivity, specificity and accuracy, respectively.
关键词
宫颈肿瘤 /
癌 /
鳞状细胞 /
抗肿瘤联合化疗方案 /
体层摄影术 /
螺旋计算机
中图分类号：
Ｒ737.33
Ｒ730.261
Ｒ814.42
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]Osman M. The role of neoadjuvant chemotherapy in the management of locally advanced cervix cancer: a systematic review[J]. Oncol Rev, 2014, 8(2): 60-66.
[2]Giuseppa S, Giuseppe S, Giuseppe LB, et al. Efficacy and tolerability of paclitaxel, ifosfamide and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma[J]. J Gynecol Oncol, 2015, 26(2): 118-124.
[3]Lee J, Kim TH, Kim GE, et al. Neoadjuvant chemotherapy followed by surgery has no therapeutic advantages over concurrent chemoradiotherapy in International Federation of Gynecology and Obstetrics stage ⅠB-ⅡB cervical cancer[J]. J Gynecol Oncol, 2016, 27(5): e52.
[4]Kim SH, Kamaya A, Willmann JK. CT Perfusion of the liver:principles and applications in oncology[J]. Radiology, 2014, 272(2): 322-344.
[5]García-Figueiras R, Goh VJ, Padhani AR, et al. CT perfusion in oncologic imaging: a useful tool[J]. AJR, 2013, 200(1): 8-19.
[6]Eilaghi A, Yeung T, d'Esterre C, et al. Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images[J]. Biomark Cancer, 2016, 8(Supply 2): 47-59.
[7]Kim HS, Kim JY, Park NH, et al. Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage ⅠB1-ⅡA cervical cancer[J]. Gynecol Oncol, 2010, 119(2): 217-224．
[8]Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions[J]. Lancet, 2016, 30, 388(10043): 518-529.
[9]董霞，王刚. 局部晚期宫颈癌新辅助化疗影响因素研究进展[J]. 中华临床医师杂志：电子版，2012，6（15）：4412-4415.
[10]Peng YH, Wang XX, Zhu JS, et al. Neo-adjuvant chemotherapy plus surgery versus surgery alone for cervical cancer: Meta-analysis of randomized controlled trials[J]. J Obstet Gynaecol Res, 2016, 42(2): 128-135.
[11]Guo L, Liu X, Wang L, et al. Outcome of international Federation of gynecology and obstetrics stage Ⅱb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study[J]. Int J Gynecol Cancer, 2015, 25(5): 910-918.
[12]Kim K, Kim MJ, Chung HH, et al. Inadvertent potential risk of neoadjuvant chemotherapy in cervical cancer[J]. Med Hypotheses, 2009, 73(6): 1005-1007.
[13]Taucher S, Steger GG, Jakesz R, et al. The potential risk of neoadjuvant chemotherapy in breast cancer patients-results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group(ABCSG-07)[J]. Breast Cancer Res Trea, 2008, 112(2): 309-316.
[14]Cibula D, Zikan M, Slama J, et al. Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer[J]. Gynecol Oncol, 2016, 143(1): 83-86.
[15]Sakuragi N, Satoh C, Takeda N, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages ⅠB, ⅡA, and ⅡB cervical carcinoma treated with radical hysterectomy[J]. Cancer, 1999, 85(7): 1547-1554.
[16]Horn LC, Bilek K, Fischer U, et al. A cut-off value of 2 cm in tumor size is of prognostic value in surgically treated FIGO stage ⅠB cervical cancer[J]. Gynecol Oncol, 2014, 134(1): 42-46.
[17]Horn LC, Fischer U, Raptis G, et al. Tumor size is of prognostic value in surgically treated FIGO stage Ⅱ cervical cancer[J]. Gynecol Oncol, 2007, 107(2): 310-315.
[18]Goh V, Glynne-Jones R. Perfusion CT imaging of colorectal cancer[J]. Br J Radiol, 2014, 87(1034): 20130811.
[19]Razek AA, Tawfik AM, Elsorogy LG, et al. Perfusion CT of head and neck cancer[J]. Eur J Radiol, 2014, 83(3): 537-544.
[20]Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer[J]. Cochrane Database Syst Rev, 2012, 12: CD007406.
[21]Lapresa M, Parma G, Portuesi R. Neoadjuvant chemotherapy in cervical cancer: an update[J]. Expert Rev Anticancer Ther, 2015, 15(10): 1171-1181.
基金
2013年甘肃卫生行业科研管理项目（GWGL2013-27）。
